The albumin-to-creatinine ratio (ACR) is a simple urine test that checks for small amounts of a protein called albumin leaking into your urine, which is one of the earliest signs of kidney damage. A normal result is less than 30 mg/g. The “random” part means the sample can be collected at any time of day, without the hassle of saving all your urine over a full 24-hour period.
What the Test Actually Measures
Healthy kidneys filter waste from your blood while keeping useful proteins, like albumin, in your bloodstream. When the kidney’s filtering units become damaged, albumin starts slipping through into your urine. The trouble is that a single measurement of albumin in urine can be misleading because your urine concentration changes throughout the day depending on how much you drink, what medications you take, and even the time of day.
That’s where creatinine comes in. Creatinine is a waste product your muscles produce at a fairly steady rate, so it serves as a built-in reference point. By dividing the albumin level by the creatinine level, the test corrects for how dilute or concentrated your urine happens to be at the moment you provide the sample. The result is a ratio that approximates what a full 24-hour urine collection would show, without the inconvenience of collecting every drop of urine for an entire day.
Why a Random Sample Works
The 24-hour urine collection used to be the standard for measuring protein loss from the kidneys. It required patients to save all urine produced over a full day in a jug, which was both cumbersome and prone to error since collections were self-directed at home. The National Kidney Foundation determined that a random, untimed spot urine sample is suitable for initial testing of albuminuria, and research has confirmed that spot ACR and 24-hour collections perform comparably for predicting major clinical outcomes like kidney failure and death.
A first-morning sample is sometimes preferred because it reduces the variability caused by physical activity and posture changes during the day, but a sample collected at any time is still clinically useful. If you’re asked not to urinate for one to two hours before your appointment, that’s to ensure the sample isn’t overly dilute.
Understanding Your Results
The American Diabetes Association and international kidney disease guidelines use three main categories:
- Normal (A1): Less than 30 mg/g. Your kidneys are filtering properly.
- Moderately increased, or microalbuminuria (A2): 30 to 300 mg/g. Small amounts of albumin are leaking through. This is the earliest detectable stage of kidney damage.
- Severely increased, or macroalbuminuria (A3): Greater than 300 mg/g. Significant protein loss is occurring, suggesting more advanced kidney damage.
There are also sex-based differences in what’s considered truly normal. For males, a ratio below 17 mg/g is normal, and for females, below 25 mg/g. These thresholds are lower than the 30 mg/g cutoff used in disease classification, which means your result could technically fall in the “normal” category but still be worth watching.
One abnormal result does not equal a diagnosis. Guidelines from KDIGO (the leading international kidney disease organization) are clear that a single test cannot confirm chronic kidney disease. You’ll need at least one repeat test, typically three months later, to rule out a temporary spike before any diagnosis is made.
What Can Cause a Temporary Spike
Several things can push albumin into your urine temporarily without any real kidney damage. These include vigorous exercise, fever, urinary tract infections, seizures, heart failure, and general conditions that increase the permeability of blood vessels. Even normal daily fluctuations in your body can cause variations. This is exactly why repeat testing matters: a single high reading may reflect something that resolves on its own.
Who Should Be Tested
ACR testing is most commonly ordered for people with type 2 diabetes. Major guidelines from the American Diabetes Association, KDIGO, and the US Kidney Disease Outcomes Quality Initiative all recommend that people with type 2 diabetes get both an ACR test and an estimated glomerular filtration rate (eGFR, a blood test measuring how well your kidneys filter) at the time of diagnosis, then at least once every year after that. People with type 1 diabetes typically start annual screening five years after diagnosis.
Beyond diabetes, testing is recommended for people with high blood pressure, heart disease, a family history of kidney disease, or other risk factors for kidney problems. If you already have confirmed kidney disease, your doctor will likely check your ACR more frequently, sometimes two to four times per year, to track how well treatment is working.
How ACR Fits Into Kidney Disease Staging
ACR doesn’t work alone. Doctors combine it with your eGFR to build a complete picture of your kidney health using what’s known as the KDIGO heat map. The eGFR tells you how well your kidneys are filtering (measured in categories from G1, normal, down to G5, kidney failure), while the ACR tells you how much structural damage exists (A1 through A3). Together, these two numbers place you in a risk category ranging from low to very high.
Someone with a normal eGFR above 90 and a normal ACR below 30 is at low risk and doesn’t have chronic kidney disease. But someone with that same normal eGFR and an ACR above 300 would be classified as high risk and referred to a kidney specialist, even though their filtration rate looks fine. The ACR can catch damage that eGFR alone would miss, which is why both tests are recommended together.
The frequency of monitoring increases as your risk category climbs. A person in a low-risk category might need testing once a year, while someone in a high-risk category may need testing three to four times per year along with a nephrology referral.
ACR and Heart Disease Risk
Albumin in the urine isn’t just a kidney problem. It’s also a marker of blood vessel damage throughout the body, which makes it a powerful predictor of cardiovascular risk. Research on patients with coronary artery disease found that even mildly elevated ACR (10 to 30 mg/g, still technically in the “normal” range) was associated with increased risk of death from heart disease. Moderately elevated ACR roughly doubled the risk of cardiovascular death, and severely elevated ACR tripled it.
This relationship held for people with and without diabetes, though the risk was amplified in those with type 2 diabetes. In that group, severely elevated ACR was associated with nearly a fourfold increase in cardiovascular death. The takeaway is that any degree of albumin leaking into urine signals stress on the vascular system, not just the kidneys. This is part of why guidelines push for routine screening in people with cardiovascular risk factors.